User Guide
Why can I only view 3 results?
You can also view all results when you are connected from the network of member institutions only. For non-member institutions, we are opening a 1-month free trial version if institution officials apply.
So many results that aren't mine?
References in many bibliographies are sometimes referred to as "Surname, I", so the citations of academics whose Surname and initials are the same may occasionally interfere. This problem is often the case with citation indexes all over the world.
How can I see only citations to my article?
After searching the name of your article, you can see the references to the article you selected as soon as you click on the details section.
 Views 20
 Downloands 1
Erkek meme kanserli hastaların analizi: tek merkez sonuçları
2021
Journal:  
Pamukkale Tıp Dergisi
Author:  
Abstract:

AMAÇ: Erkek meme kanseri (EMK) tüm meme kanserlerinin % 1-2’sini oluşturan nadir kanserlerdir. Çalışmamızda kliniğimize başvuran EMK tanılı hastaların klinikopatolojik bulgularını, tedavi yaklaşımımızı ve sonuçlarını incelemeyi amacladık. GEREÇ-YÖNTEM: Pamukkale Üniversitesi Tıp Fakültesi Genel Cerrahi kliniğinde 2006-2020 yılları arasında meme kanseri nedeniyle tedavi edilen 12 erkek hastanın kliniko-patolojik özellikleri, uygulanan tedaviler ve sonuçları retrospektif olarak incelendi. BULGULAR: Hastaların yaş ortalaması 59 yıl (39-82)olup, %66,7’si 50 yaş üzerindeydi. Ortalama tümör boyutu 27 mm (4-42) olarak saptandı. Hastaların %58,3 eşlik eden herhangi bir hastalık saptanmadı. Hastaların tamamı kitle şikayeti ile başvurmuştu ve %66,7’sinde kitle santral yerleşimliydi. Hastaların %66,7’sinde tümör sağ meme yerleşimliydi. Hastaların %91,7’sinde ailede meme kanseri hikayesi yoktu. Hastaların 2’sinde (%16,6) meme dışında 2. bir malignite (1 hastada mide kanseri, 1 hastada non-Hodgkin lenfoma)mevcuttu. Bir hasta da izlemde kontralateral meme kanseri görüldü. Hastaların %91,7 modifiye radikal mastektomi (MRM)operasyonu yapıldı. En sık görülen histolijik tip (%83,3) invaziv duktal karsinomdu, Hastaların %58,3’ü evre 2b ve üzerindeydi. Hastaların %25’i luminal A, %50’si luminal B, %8,3’ü Her 2 + ve %16,7’si üçlü negatif moleküler alt tipteydi. Hastaların %83,3’ü adjuvan kemoterapi, %50’si adjuvan radyoterapi ve %58,3’ü adjuvan endokrin tedavisi aldı. Hastaların ortalama izlem süresi 68 ay (6-184 ay) ve izlemde 1 hastada lokal nüks, 3 hastada sistemik metastaz ve 1 hastada kontralateral meme kanseri görüldü. SONUÇ: Çalışmamızda nadir bir hastalık olan EMK’nin klinikopatolojik özellikleri değerlendirilmiştir. Özellikle 50 yaş üstü erkek hastalarda memede kitle mevcudiyetinde EMK konusunda dikkatli olunmalı ve tedavi planlamasında hastalığın genetik temeli gözardı edilmemelidir.

Keywords:

Analysis of Men's Breast Cancer Patients: Single Center Results
2021
Author:  
Abstract:

Male Breast Cancer (EMC) is a rare cancer that accounts for 1-2% of all breast cancers. In our study, we aimed at examining the clinical pathological findings, our treatment approach and the results of EMK-defined patients who apply to our clinic. The Clinic of General Surgery at the Pamukkale University School of Medicine examined the clinico-patological characteristics, therapies and results of 12 male patients treated for breast cancer between 2006 and 2020. The average age of patients was 59 years (39-82) and 66.7 percent were over 50 years. The average tumor size was 27 mm (4-42). No disease was identified that was accompanied by 58.3% of patients. All of the patients applied with a mass complaint and 66.7 percent of the mass centers were settled. In 66.7 percent of patients, the tumor was placed in the right breast. In 91.7 percent of patients, there was no history of breast cancer in the family. In 2 patients (16.6 percent) there was a second malignity (in 1 patient stomach cancer, in 1 patient non-Hodgkin lymphoma). One patient was also diagnosed with contralateral breast cancer. 91.7 percent of patients received modified radical mastectomy (MRM) surgery. The most common type of histolytic (83.3%) was invasive duktal carcinoma, with 58.3% of patients in stage 2b and above. 25 percent of patients were luminal A, 50 percent luminal B, 8.3 percent each 2+ and 16.7 percent triple negative molecular subtype. 83.3% of patients received adjuvant chemotherapy, 50% received adjuvant radiotherapy and 58.3% received adjuvant endocrine therapy. The patient's average monitoring period was 68 months (6-184 months) and in the monitoring 1 patient had local nurses, 3 patients had systemic metastases and 1 patient had contra-later breast cancer. The clinical pathological characteristics of EMK, which is a rare disease, have been evaluated in our study. Especially in male patients over the age of 50 should be cautious about EMC in the mass presence in the breast and the genetic basis of the disease should not be neglected in the treatment planning.

Keywords:

0
2021
Author:  
Keywords:

Citation Owners
Information: There is no ciation to this publication.
Similar Articles












Pamukkale Tıp Dergisi

Field :   Sağlık Bilimleri

Journal Type :   Uluslararası

Metrics
Article : 948
Cite : 1.240
Pamukkale Tıp Dergisi